Antaros Medical

What Antaros Medical does

Antaros Medical is a Swedish imaging contract research organization (CRO) headquartered in Mölndal, Sweden, founded in 2014. The company specializes in advanced imaging-based services — including MRI, biopsy techniques, and functional tests — used to evaluate body composition changes during clinical trials in obesity and metabolic disease. Its core technical offering addresses a specific pain point for pharmaceutical sponsors: the precise measurement and interpretation of muscle and fat tissue changes during weight loss, supporting drug development programs in metabolic disease where body composition outcomes are increasingly important clinical endpoints.

The company operates a B2B services model, selling quote-based study contracts to pharmaceutical and biotech clients. Its go-to-market is vertical, targeting sponsors of obesity and metabolic disease clinical trials as its single primary customer segment. The technology stack centers on validated imaging protocols, biopsy methodology, and functional testing workflows rather than a software platform; no APIs, SDKs, or digital products are disclosed.

On May 19, 2026, Lauxera Capital Partners — a Paris- and San Francisco-based growth buyout and growth equity firm — completed a majority stake acquisition of Antaros Medical as one of the first two investments from its €520 million Lauxera Growth II fund. The fund's stated mandate is to bridge European healthtech innovation with U.S. commercial scale, with typical equity checks of €20–50 million per company. Antaros continues to operate as a standalone portfolio company under Lauxera's controlling ownership, with 101–250 employees and leadership including CEO Johannes Hulthe (with Richard Olbe also referenced as CEO in source material) and Caleb Roberts as Director of Business Development.

Name

Antaros Medical

Website

https://antarosmedical.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

101–250 employees

Short description

Antaros Medical is a Swedish imaging CRO providing advanced MRI, biopsy, and functional testing services for body composition analysis in obesity and metabolic disease clinical trials for pharmaceutical and biotech sponsors.

Ownership category

akta.pro rank

Product category

Clinical Research Services

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

• Imaging contract research
• Clinical trial services
• Body composition analysis
• Metabolic disease research
• MRI imaging services

Headquarters

HQ city

Mölndal

HQ country

Sweden

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Core offering

Antaros Medical is a Swedish imaging contract research organization (CRO) that provides specialized imaging services for clinical trials in obesity and metabolic disease research. The company applies advanced imaging techniques including MRI, biopsy, and functional tests to evaluate body composition changes during weight loss for pharmaceutical and biotech sponsors. Its core deliverable is study-specific imaging and analysis support that helps trial sponsors interpret muscle and fat composition shifts during clinical development.

Product overview

Antaros Medical is a Swedish imaging contract research organization (CRO) that provides specialized imaging services for clinical trials in obesity and metabolic disease research. The company offers advanced imaging techniques including MRI, biopsy, and functional tests for evaluating body composition changes during weight loss in clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

• Imaging CRO Services for Obesity and Metabolic Disease

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered minor.

• XtalksminorStrategic or Co-development Partner · 28 April 2026Antaros Medical is featured as a speaker in a collaborative webinar hosted by Xtalks alongside Profil and Steno Diabetes Centre Aarhus, focusing on muscle composition assessment techniques in clinical trials for obesity and metabolic disease research.
• ProfilminorStrategic or Co-development Partner · 28 April 2026Antaros Medical is collaborating with Profil and Steno Diabetes Centre Aarhus as featured speakers in a webinar focused on assessing muscle composition changes during weight loss in clinical trials, discussing MRI, biopsy, and functional test methodologies.
• Steno Diabetes Centre AarhusminorStrategic or Co-development Partner · 28 April 2026Antaros Medical is collaborating with Antaros Medical and Profil as featured speakers in a webinar focused on assessing muscle composition changes during weight loss in clinical trials, discussing MRI, biopsy, and functional test methodologies for obesity and metabolic disease research.

Recent moves3 records

Expansion highlights4 records

Direct peers

• Clario (formerly BioClinica / ERT): Clario is a leading imaging core lab CRO that provides centralized MRI and other imaging endpoint services for clinical trials, including in metabolic and cardiovascular indications — directly comparable to Antaros's imaging CRO model.
• IXICO plc: IXICO provides imaging biomarkers and AI-enabled analytics for clinical trials, with core capabilities in MRI quantification — a direct functional peer to Antaros's MRI-based body composition methodology.
• Intrinsic Imaging: Intrinsic Imaging is an imaging core lab CRO providing centralized imaging review and analysis for clinical trials, comparable to Antaros in serving pharma sponsors with specialized imaging endpoint capabilities.

Broad incumbents

• ICON plc: ICON is one of the largest global CROs with established medical imaging services (including ICON Medical Imaging). It competes for the same pharma trial imaging endpoint budgets as Antaros but across all therapeutic areas.
• Medpace Holdings: Medpace is a mid-to-large CRO with growing imaging capabilities and a strong metabolic/obesity trial franchise. It represents the 'in-house' alternative that pharma sponsors may choose over a specialist like Antaros.
• Parexel International: Parexel is a large global CRO with established imaging and biomarker capabilities across multiple therapeutic areas, including metabolic disease — a broad incumbent competing for the same sponsor imaging budgets as Antaros.

Emerging players

• Vivosense: Vivosense develops imaging and digital biomarkers for clinical trials, including metabolic and cardiometabolic indications — an emerging specialist peer with overlapping methodology and customer base.
• Perspectum: Perspectum provides quantitative MRI-based diagnostics and imaging biomarkers, with applications in metabolic and liver disease — adjacent to Antaros's body composition work and serving overlapping pharma sponsors.
• Resonance Health: Resonance Health provides FDA-cleared MRI image analysis services (notably for liver fat / iron quantification), with applicability to metabolic disease trials — an adjacent specialist peer in MRI-based body composition.
• Profil: Profil is a specialized metabolic disease CRO running early-phase clinical pharmacology studies, with whom Antaros co-presents. It is a complementary (not direct) peer serving overlapping obesity/metabolic sponsors.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antaros Medical